Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome

BMC Veterinary Research

Alexander J German⁴  Penelope J Morris⁵  Vincent Biourge³  Daniel J Cuthbertson²  Shelley L Holden⁴  Jose J Ceron¹  Asta Tvarijonaviciute¹ 

[1] Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, 30100, Murcia, Spain;Department of Obesity and Endocrinology, University of Liverpool, University Hospital Aintree, Longmoor Lane, Fazakerley, Liverpool, L9 7AL, United Kingdom;Royal Canin Research Center, B.P.4 – 650 Avenue de la Petite Camargue, 30470, Aimargues, France;Department of Obesity and Endocrinology, University of Liverpool, Leahurst Campus, Chester High Road, Neston, Wirral, CH64 7TE, United Kingdom;The WALTHAM Centre for Pet Nutrition, Freeby Lane, Waltham-on-the-Wolds, Melton Mowbray, LE14 4RT, UK

关键词: Adiponectin;    Weight loss;    Insulin resistance;    Canine;   

Others  :  1119740
DOI  :  10.1186/1746-6148-8-147

 received in 2012-05-24, accepted in 2012-08-22,  发布年份 2012

【 摘 要 】

Background

Recently, metabolic syndrome (MS) has gained attention in human metabolic medicine given its associations with development of type 2 diabetes mellitus and cardiovascular disease. Canine obesity is associated with the development of insulin resistance, dyslipidaemia, and mild hypertension, but the authors are not aware of any existing studies examining the existence or prevalence of MS in obese dogs.

Thirty-five obese dogs were assessed before and after weight loss (median percentage loss 29%, range 10-44%). The diagnostic criteria of the International Diabetes Federation were modified in order to define canine obesity-related metabolic dysfunction (ORMD), which included a measure of adiposity (using a 9-point body condition score [BCS]), systolic blood pressure, fasting plasma cholesterol, plasma triglyceride, and fasting plasma glucose. By way of comparison, total body fat mass was measured by dual-energy X-ray absorptiometry, whilst total adiponectin, fasting insulin, and high-sensitivity C-reactive protein (hsCRP) were measured using validated assays.

Results

Systolic blood pressure (P = 0.008), cholesterol (P = 0.003), triglyceride (P = 0.018), and fasting insulin (P < 0.001) all decreased after weight loss, whilst plasma total adiponectin increased (P = 0.001). However, hsCRP did not change with weight loss. Prior to weight loss, 7 dogs were defined as having ORMD, and there was no difference in total fat mass between these dogs and those who did not meet the criteria for ORMD. However, plasma adiponectin concentration was less (P = 0.031), and plasma insulin concentration was greater (P = 0.030) in ORMD dogs.

Conclusions

In this study, approximately 20% of obese dogs suffer from ORMD, and this is characterized by hypoadiponectinaemia and hyperinsulinaemia. These studies can form the basis of further investigations to determine path genetic mechanisms and the health significance for dogs, in terms of disease associations and outcomes of weight loss.

【 授权许可】

   
2012 Tvarijonaviciute et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Leroith D: Pathophysiology of the metabolic syndrome: implications for the cardiometabolic risks associated with type 2 diabetes. American Journal of Medical Science 2012, 343:13-16.
• [2]Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA: American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arteriosclerosis Thrombosis and Vascular Biology 2004, 24:e19-e24.
• [3]Sanad M, Gharib A: Evaluation of microalbuminuria in obese children and its relation to metabolic syndrome. Pediatric Nephrology 2011, 26:2193-2199.
• [4]Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology 2011, 6:2364-2373.
• [5]Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD: Metabolic Syndrome and Insulin Resistance as Risk Factors for Development of Chronic Kidney Disease and Rapid Decline in Renal Function in Elderly. Journal of Clinical Endocrinology and Metabolism 2012, 97:1268-1276.
• [6]Johnson PJ: The equine metabolic syndrome peripheral Cushing’s syndrome. Veterinary Clinics of North America Equine Practice 2002, 18:271-293.
• [7]Treiber KH, Kronfeld DS, Hess TM, Byrd BM, Splan RK, Staniar WB: Evaluation of genetic and metabolic predispositions and nutritional risk factors for pasture-associated laminitis in ponies. Journal of the American Veterinary Medical Association 2006, 228:1538-1545.
• [8]Frank N, Elliott SB, Brandt LE, Keisler DH: Physical characteristics, blood hormone concentrations, and plasma lipid concentrations in obese horses with insulin resistance. Journal of the American Veterinary Medical Association 2006, 228:1383-1390.
• [9]Frank N: Equine metabolic syndrome. Journal of Equine Veterinary Science 2009, 29:259-267.
• [10]Frank N: Equine metabolic syndrome. Veterinary Clinics of North America Equine Practice. 2011, 27:73-92.
• [11]Jeusette IC, Lhoest ET, Istasse LP, Diez MO: Influence of obesity on plasma lipid and lipoprotein concentrations in dogs. American Journal of Veterinary Research 2005, 66:81-86.
• [12]German AJ, Hervera M, Hunter L, Holden SL, Morris PJ, Biourge V, Trayhurn P: Improvement in insulin resistance and reduction in plasma inflammatory adipokines after weight loss in obese dogs. Domestic Animal Endocrinology 2009, 37:214-222.
• [13]Yamka RM, Friesen KG, Frantz NZ: Identification of canine markers related to obesity and the effects of weight loss on the markers of interest. International Journal of Applied Research in Veterinary Medicine 2006, 4:282-292.
• [14]Lund EM, Armstrong PJ, Kirk CA, Klausner JS: Prevalence and risk factors for obesity in adult dogs from private US veterinary practices. International Journal of Applied Research in Veterinary Medicine 2006, 4:177-186.
• [15]Kealy RD, Lawler DF, Ballam JM, Mantz SL, Biery DN, Greeley EH, Lust G, Segre M, Smith GK, Stowe HD: Effects of diet restriction on life span 481 and age-related changes in dogs. Journal of the American Veterinary Medical Association 2002, 220:1315-1320.
• [16]German AJ, Holden SL, Bissot T, Hackett RM, Biourge V: Dietary energy restriction and successful weight loss in obese client-owned dogs. Journal of Veterinary Internal Medicine 2007, 21:1174-1180.
• [17]Tvarijonaviciute A, Ceron JJ, Holden SL, Biourge V, Morris PJ, German AJ: Effect of weight loss in obese dogs on a range of renal biomarkers. Journal of Veterinary Internal medicine 2012, 26:809.
• [18]German AJ, Holden SL, Bissot T, Morris PJ, Biourge V: A high protein high fibre diet improves weight loss in obese dogs. The Veterinary Journal 2010, 183:294-297.
• [19]Laflamme D: Development and validation of a body condition score system for dogs. Canine Practice 1997, 22:10-15.
• [20]National Research Council (NRC). Energy: Nutrient Requirements of Dogs and Cats. Washington DC: The National Academies Press; 2006:28-48.
• [21]Raffan E, Holden SL, Cullingham F, Hackett RM, Rawlings JM, German AJ: Standardized positioning is essential for precise determination of body composition using dual-energy x-ray absorptiometry in dogs. Journal of Nutrition 2006, 136:1976-1978.
• [22]International diabetes federation: Worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome webcite
• [23]International Renal Interest Society: IRIS staging of CKD. http://www.iris-kidney.com/guidelines/en/staging_ckd.shtml webcite
• [24]Tvarijonaviciute A, Martínez-Subiela S, Ceron JJ: Validation of 2 commercially available enzyme-linked immunosorbent assays for adiponectin determination in canine serum samples. Canadian Journal of Veterinary Research 2010, 74:279-285.
• [25]Öberg J, Fall T, Lilliehöök I: Validation of a species-optimized enzyme-linked immunosorbent assay for determination of serum concentrations of insulin in dogs. Veterinary Clinical Pathology 2011, 40:66-73.
• [26]Parra MD, Tuomola M, Cabezas-Herrera J, Cerón JJ: Analytical and clinical validation of a time-resolved immunofluorometric assay (TR-IFMA) for canine C-reactive protein in serum. Veterinary Research Communications 2006, 30:113-126.
• [27]Liddell FDK: Simplified exact analysis of case-referent studies; matched pairs; dichotomous exposure. Journal of Epidemiology and Community Health 1983, 37:82-84.
• [28]Tvarijonaviciute A, Tecles F, Martínez-Subiela S, Ceron JJ: Effects of weight loss on inflammatory biomarkers in obese dog. Veterinary Journal 2012. http://dx.doi.org/10.1016/j.tvjl.2012.02.015 webcite
• [29]World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: World Health Organization; 1999.
• [30]Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B, European Group For The Study Of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes and Metabolism 2002, 28:364-376.
• [31]Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001, 285:2486-2497.
• [32]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [33]Chapman MJ: Comparative analysis of mammalian plasma lipoproteins. Methods in Enzymology 1986, 128:70-143.
• [34]Tvarijonaviciute A, Tecles F, Ceron JJ: Relationship between serum butyrylcholinesterase and obesity in dogs: a preliminary report. Veterinary Journal 2010, 186:197-200.
• [35]Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Archives of Internal Medicine 2003, 163:427-436.
• [36]Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM: Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. Journal of Clinical Endocrinology and Metabolism 2004, 89:2697-26703.
• [37]Kahn R: Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007, 115:1806-10.
• [38]Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126-1133.
• [39]Zoccali C, Mallamaci F, Tripepi G: Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney International Supplements 2003, 2003(84):S65-S68.
• [40]Wakshlag JJ, Struble AM, Levine CB, Bushey JJ, Laflamme DP, Long GM: The effects of weight loss on adipokines and markers of inflammation in dogs. British Journal of Nutrition 2011, 106:S11-S14.
• [41]Tarkkinen P, Palenius T, Lövgren T: Ultrarapid, ultrasensitive one-step kinetic immunoassay for C-reactive protein (CRP) in whole blood samples: measurement of the entire CRP concentration range with a single sample dilution. Clinical Chemistry 2002, 48:269-277.
• [42]Verkest KR, Fleeman LM, Morton JM, Ishioka K, Rand JS: Compensation for obesity-induced insulin resistance in dogs: assessment of the effects of leptin, adiponectin, and glucagon-like peptide-1 using path analysis. Domestic Animal Endocrinology 2011, 41:24-34.
• [43]Mori N, Lee P, Yamamoto I, Arai T: Elevated plasma adiponectin level and peripheral blood leukocyte adiponectin receptor expression in dogs suffering from insulin deficiency. The Open Veterinary Science Journal 2012, 6:1-7.
• [44]Radin MJ, Sharkey LC, Holycross BJ: Adipokines: a review of biological and analytical principles and an update in dogs, cats, and horses. Veterinary Clinical Pathology 2009, 38:136-156.
• [45]Carpentier YA, Portois L, Malaisse MJ: n-3 Fatty acids and the metabolic syndrome. American Journal of Clinical Nutrition 2006, 83:1499S-1504S.
• [46]Knudson JD, Dincer D, Bratz IN, Sturek M, Dick GM, Tune JD: Mechanisms of Coronary Dysfunction in Obesity and Insulin Resistance. Microcirculation 2007, 2007(14):317-338.
• [47]Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K: The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. Annals of Internal Medicine 2005, 143:722-728.
• [48]Shea JL, Randell EW, Sun G: The prevalence of metabolically healthy obese subjects defined by BMI and dual-energy X-ray absorptiometry. Obesity 2011, 19:624-630.
• [49]De Fronzo RA, Soman V, Sherwin RS, et al.: Insulin binding to monocytes and insulin action in human obesity starvation and refeeding. Journal of Clinical Investigation 1978, 62:204-213.
• [50]Bergman RN, Ider YZ, Bowden CR, et al.: Quantitative estimation of insulin sensitivity. American Journal of Physiology 1979, 236:E667-E677.